Back to Sites

Bronx-Lebanon Hospital IMPAACT

Site Number

5114

Address

Bronx-Lebanon Hosp. IMPAACT CRS
1685 Morris Ave
Suite 1 G
Bronx, NY 10457
United States of America

IMPAACT Members at this Site

Martha Cavallo CRS Coordinator

Mahboobullah Mirza-Baig Investigator

Caroline Nubel Investigator

Studies at this Site

P1093: PK, Safety, Tolerability and Antiviral Activity of Dolutegravir

DAIDS Number

11773

Research Area

Therapeutics

P1115: Very Early Intensive Treatment of Infants Living with HIV to Achieve HIV Remission: A Phase I/II Proof of Concept Study

DAIDS Number

11954

Research Area

Cure and Immunotherapy

Study Status

Enrolling

IMPAACT 2026: Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum.

DAIDS Number

38609

Research Area

Therapeutics

Study Status

Closed to Follow Up

IMPAACT 2023: A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1

DAIDS Number

38637

Research Area

Therapeutics

Study Status

Closed to Follow Up

IMPAACT 2028: Long-Term Clinical, Immunologic, and Virologic Profiles of Children who Received Early Treatment for HIV

DAIDS Number

38693

Research Area

Cure and Immunotherapy

Study Status

Participants Off Study and Primary Analysis Completed

IMPAACT 2029: Phase I/II Study of Switching to Fixed Dose Combination Dolutegravir/Rilpivirine among Virologically Suppressed Children and Adolescents Living with HIV

DAIDS Number

38717

Research Area

Treatment

Study Status

Withdrawn

IMPAACT 2032: Pharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant and Non-Pregnant Women in the United States.

DAIDS Number

38746

Research Area

Therapeutics

Study Status

Participants Off Study and Primary Analysis Completed

IMPAACT 2017: MOCHA

DAIDS Number

30070

Research Area

Therapeutics

Study Status

Participants Off Study and Primary Analysis Completed

IMPAACT 2037: Open-Label, Phase I Study of the Safety and Pharmacokinetics of PGT121.414.LS alone and in combination with VRC07-523LS in Infants Exposed to HIV-1

DAIDS Number

38962

Research Area

Therapeutics

Study Status

Enrolling

IMPAACT 2041: Phase I/II Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women with Hepatitis C with and without HIV

DAIDS Number

39052

Research Area

Therapeutics

Study Status

Open to Accrual